MedPath

LAURUS LABS LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

21

FDA:19
PHILIPPINES:2

Drug Approvals

Ursodiol

Approval Date
Mar 11, 2024
FDA

Atorvastatin Calcium

Approval Date
Jan 29, 2024
FDA

HYDROXYCHLOROQUINE SULFATE

Approval Date
Jan 5, 2024
FDA

Hydroxychloroquine Sulfate

Approval Date
Jan 5, 2024
FDA

Atazanavir

Approval Date
Dec 5, 2023
FDA

Lopinavir and Ritonavir

Approval Date
Oct 20, 2023
FDA

Metformin Hydrochloride

Approval Date
Sep 21, 2023
FDA

Abacavir and Lamivudine

Approval Date
Sep 2, 2023
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

APAC Biopharma Trends: ADCs, CGTs, AI, and Clinical Trial Dominance in 2025

• Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies. • Cell and gene therapies (CGTs) are experiencing a surge in APAC, with China leading in CAR-T clinical trials and approvals, indicating a growing focus on innovative treatments for oncology and other diseases. • Artificial intelligence (AI) is becoming integral in APAC's pharmaceutical sector, enhancing drug discovery, clinical trials, and personalized medicine, with AI-designed drugs nearing regulatory approval. • The APAC region is solidifying its dominance in clinical trials, driven by a large patient population and regulatory reforms, particularly in oncology, attracting both local and global pharmaceutical firms.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.